06
069620.KO Daewoong Pharma
- Market cap
- KRW 1.23T
- P/E
- 6.1x
- P/B
- 1.11x
- ROE
- 11.1%
- Dividend yield
- 0.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 069620.KO undervalued?
Graham number069620.KO trades 45.3% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Daewoong Pharma fundamental analysis
No fundamental analysis for Daewoong Pharma yet.
Daewoong Pharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 Ig…
Full company profileDaewoong Pharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Daewoong Pharma annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 884B | 960B | 1.03T | 1.11T | 1.06T | 1.15T | 1.28T | 1.38T | 1.42T | 1.57T | 1.65T |
| Gross Profit | 374B | 407B | 410B | 478B | 447B | 545B | 639B | 688B | 734B | 823B | 861B |
| Operating Income | 25.9B | 39.0B | 24.6B | 44.7B | 17.0B | 88.9B | 95.8B | 123B | 148B | 197B | 181B |
| EBITDA | - | 84.5B | 60.3B | 73.6B | 65.1B | 71.1B | 86.4B | 179B | 113B | 255B | 292B |
| Net Income | 27.0B | 31.6B | -15.2B | 22.0B | 12.8B | 24.7B | 42.2B | 122B | 24.7B | 196B | 119B |
| EPS | - | 3,060 | -1,468 | 2,132 | 1,185 | 2,228 | 3,816 | 10,580 | 2,150 | 17,022 | 10,302 |
| Balance Sheet | |||||||||||
| Total Assets | 1.14T | 1.21T | 1.21T | 1.25T | 1.37T | 1.42T | 1.56T | 1.57T | 1.98T | 2.36T | 2.54T |
| Total Liabilities | 540B | 582B | 600B | 610B | 672B | 713B | 822B | 763B | 1.05T | 1.23T | 1.35T |
| Shareholders' Equity | 499B | 519B | 494B | 519B | 551B | 574B | 608B | 803B | 795B | 1.01T | 1.06T |
| Cash & Short-term Investments | 78.3B | 91.1B | 65.3B | 32.1B | 72.3B | 75.9B | 103B | 17.2B | 103B | 169B | 155B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.4B | 104B | 47.5B | 57.6B | 101B | 40.0B | 118B | 133B | 51.5B | 149B | 129B |
| Capital Expenditure | 163B | 69.1B | 57.0B | 22.3B | 26.5B | 29.1B | 65.2B | 119B | 229B | 241B | 324B |
| Free Cash Flow | - | 7.18B | -9.56B | 7.49B | 41.3B | -34.8B | 4.91B | 13.9B | -178B | -92.2B | -195B |
| Ratios | |||||||||||
| ROE | 5.4% | 6.1% | -3.1% | 4.2% | 2.3% | 4.3% | 6.9% | 15.2% | 3.1% | 19.5% | 11.1% |
| ROA | 2.4% | 2.6% | -1.3% | 1.8% | 0.9% | 1.7% | 2.7% | 7.8% | 1.3% | 8.3% | 4.7% |
| Net Profit Margin | 3.1% | 3.3% | -1.5% | 2.0% | 1.2% | 2.1% | 3.3% | 8.9% | 1.7% | 12.5% | 7.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Daewoong Pharma dividends
- Dividend yield
- 0.66%
- Forward dividend
- 600.00 KRW
- Payout ratio
- 4.1%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 8.08B | 702 | 4.1% |
| 2024 | KRW 7.74B | 673 | 31.3% |
| 2023 | KRW 6.64B | 577 | 5.5% |
| 2022 | KRW 8.07B | 729 | 19.1% |
| 2021 | KRW 6.46B | 583 | 26.2% |
| 2020 | KRW 6.19B | 575 | 48.6% |
| 2019 | KRW 6.19B | 600 | 28.1% |
| 2018 | KRW 6.19B | 600 | - |
| 2017 | KRW 6.19B | 600 | 19.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.03:1 on Dec 27, 2012.
Who owns Daewoong Pharma
- Insiders 61.48%
- Institutions 19.58%
- Public & others 18.94%
- Shares outstanding 11.5M
- Free float 5.38M
Daewoong Pharma company profile
- Company name
- Daewoong Pharma
- Ticker
- 069620.KO
- ISIN
- KR7069620003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,893
- Fiscal year end
- December
- Address
- 12, Bongeunsa-ro 114-gil, Seoul, South Korea, 135-715
- Phone
- 82 2 550 8209
- Website
- daewoong.com
About Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.
Daewoong Pharma management
3- Mr. Chang-Jae LeeCEO & Executive Director · born 1977
- Mr. Seongsoo ParkCEO & Executive Director · born 1976
- Eunkyeong ParkExecutive Director